Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹2,149.90
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹106.27B
Enterprise Value₹105.98B
Total Cash (Recent Filing)₹3.81B
Total Debt (Recent Filing)₹16.07M
Price to Earnings (P/E)54.6
Beta1.00
Next Earnings
May 21, 2026EPS Estimate
8.9Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)6.30
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)9.60
Price to Sales (P/S)14.50
P/FCF Ratio127.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.26
Revenue Forecast (FY)₹14.20B
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA low debt-to-equity profile and high equity ratio reduce solvency risk and preserve financial flexibility over time. This durability supports recurring capital spending, R&D and capacity builds without reliance on expensive external financing, improving resilience in downturns.
Specialized Fermentation API CapabilitiesSpecialization in complex fermentation-based APIs creates a technical moat: high process know-how, regulatory experience and customer stickiness. These barriers support durable contract wins, pricing power and entry into regulated markets that sustain long-term revenue visibility.
Consistent Operating Cash GenerationSteady positive operating cash flow and favorable cash conversion from profits provide internal funding for capex, working capital and selective investments. This cash-generation strength supports self-funded growth and reduces dependency on debt or equity raises over the medium term.
Bears Say
Inconsistent Free Cash Flow GrowthFluctuating free cash flow growth can constrain the firm's ability to sustainably fund expansions, acquisitions or higher R&D intensity. Over months to years this variability forces conservative capital allocation, may delay scale investments, and increases sensitivity to operating shocks.
Slight Gross Margin PressureA declining gross margin, even if slight, can erode operating leverage and reduce funds available for reinvestment and R&D. If structural (input costs or pricing pressure), it may compress long-term profitability and weaken the ability to finance capacity expansion internally.
Modest Revenue Growth And EPS DeclineModest top-line growth combined with negative EPS growth points to limited earnings momentum and potential margin or mix headwinds. Over the medium term this can limit reinvestment capacity, slow market share gains, and pressure returns to shareholders if not reversed.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹2149.90 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹106.27B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is in 23 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate is 8.9.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―